25B-NBOMe

25B-NBOMe is a psychedelic that has hardly been researched to date and is effective even at very low doses (microgram range). Psychedelics can strongly alter the perception of reality (e.g. visual perceptual changes). It has a very strong effect on the cardiovascular system, which means that overdoses can also have threatening consequences on a physical level. 25B-NBOMe is thought to have a vasoconstrictive effect, which can be particularly dangerous at high doses (increased heart rate, increased body temperature and increased blood pressure).

INFORMATION ON RISK REDUCTIONINFORMATION ON RESEARCH CHEMICALS

25B-NBOMe has a strong hallucinogenic effect and is still very little researched. According to consumers, the effect occurs even at very low doses (microgram range!). This makes dosing difficult and the risk of overdosing is increased. Some phenethylamines have a very strong effect on the cardiovascular system, which means that overdoses can also have dangerous consequences on a physical level. 25B-NBOMe has a vasoconstrictive effect, which can be particularly dangerous at high doses (increased heart rate, increased body temperature and increased blood pressure). The combination with other substances can also lead to interactions that increase the risk of negative effects and/or overdoses.

25B-NBOMe belongs to the group of phenethylamines (such as amphetamine and MDMA). The chemical structure of 25B-NBOMe is a derivative of 2C-B.

25B-NBOMe has been included in the Narcotic Substances Act (SMG) since June 2019. The acquisition, possession, import and export, transfer to and procurement for others (transfer and sale) are punishable by law. Consumers who violate the SMG must expect a mandatory visit to a public health officer (in Vienna: the outpatient centre of the Addiction and Drug Coordination). There, health-related measures may be ordered and a drug test may be expected. If you adhere to these requirements, there will be no court proceedings.

Status: July 2022